224 related articles for article (PubMed ID: 17572073)
1. Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase.
Kaiserová H; Simůnek T; van der Vijgh WJ; Bast A; Kvasnicková E
Biochim Biophys Acta; 2007 Sep; 1772(9):1065-74. PubMed ID: 17572073
[TBL] [Abstract][Full Text] [Related]
2. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
3. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials.
Bast A; Haenen GR; Bruynzeel AM; Van der Vijgh WJ
Cardiovasc Toxicol; 2007; 7(2):154-9. PubMed ID: 17652822
[TBL] [Abstract][Full Text] [Related]
4. Protectors against doxorubicin-induced cardiotoxicity: flavonoids.
Bast A; Kaiserová H; den Hartog GJ; Haenen GR; van der Vijgh WJ
Cell Biol Toxicol; 2007 Jan; 23(1):39-47. PubMed ID: 17063376
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial resveratrol and quercetin polymeric micelles mitigate doxorubicin induced cardiotoxicity in vitro and in vivo.
Cote B; Carlson LJ; Rao DA; Alani AWG
J Control Release; 2015 Sep; 213():128-133. PubMed ID: 26160305
[TBL] [Abstract][Full Text] [Related]
6. The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells.
Abou El Hassan MA; Heijn M; Rabelink MJ; van der Vijgh WJ; Bast A; Hoeben RC
Cancer Gene Ther; 2003 Apr; 10(4):270-7. PubMed ID: 12679799
[TBL] [Abstract][Full Text] [Related]
7. Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity.
van Acker FA; Boven E; Kramer K; Haenen GR; Bast A; van der Vijgh WJ
Clin Cancer Res; 2001 May; 7(5):1378-84. PubMed ID: 11350909
[TBL] [Abstract][Full Text] [Related]
8. A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro.
Abou-El-Hassan MA; Rabelink MJ; van der Vijgh WJ; Bast A; Hoeben RC
Br J Cancer; 2003 Dec; 89(11):2140-6. PubMed ID: 14647150
[TBL] [Abstract][Full Text] [Related]
9. New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity.
van Acker FA; Hulshof JW; Haenen GR; Menge WM; van der Vijgh WJ; Bast A
Free Radic Biol Med; 2001 Jul; 31(1):31-7. PubMed ID: 11425487
[TBL] [Abstract][Full Text] [Related]
10. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.
Bures J; Jirkovska A; Sestak V; Jansova H; Karabanovich G; Roh J; Sterba M; Simunek T; Kovarikova P
Toxicology; 2017 Dec; 392():1-10. PubMed ID: 28941780
[TBL] [Abstract][Full Text] [Related]
11. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
12. Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents.
Piska K; Koczurkiewicz P; Bucki A; Wójcik-Pszczoła K; Kołaczkowski M; Pękala E
Invest New Drugs; 2017 Jun; 35(3):375-385. PubMed ID: 28283780
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of selected flavonoids on in vitro daunorubicin-induced cardiotoxicity.
Mojzisová G; Mirossay L; Kucerová D; Kyselovic J; Mirossay A; Mojzis J
Phytother Res; 2006 Feb; 20(2):110-4. PubMed ID: 16444662
[TBL] [Abstract][Full Text] [Related]
14. Structural aspects of antioxidant activity of flavonoids.
van Acker SA; van den Berg DJ; Tromp MN; Griffioen DH; van Bennekom WP; van der Vijgh WJ; Bast A
Free Radic Biol Med; 1996; 20(3):331-42. PubMed ID: 8720903
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).
Gonzalez-Covarrubias V; Kalabus JL; Blanco JG
Pharm Res; 2008 Jul; 25(7):1730-4. PubMed ID: 18449627
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
Ammar el-SM; Said SA; Suddek GM; El-Damarawy SL
Can J Physiol Pharmacol; 2011 Apr; 89(4):269-76. PubMed ID: 21526973
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids.
Hüsken BC; de Jong J; Beekman B; Onderwater RC; van der Vijgh WJ; Bast A
Cancer Chemother Pharmacol; 1995; 37(1-2):55-62. PubMed ID: 7497597
[TBL] [Abstract][Full Text] [Related]
18. Screening of antioxidants from medicinal plants for cardioprotective effect against doxorubicin toxicity.
Wattanapitayakul SK; Chularojmontri L; Herunsalee A; Charuchongkolwongse S; Niumsakul S; Bauer JA
Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):80-7. PubMed ID: 15667600
[TBL] [Abstract][Full Text] [Related]
19. The Role of Flavonoids as a Cardioprotective Strategy against Doxorubicin-Induced Cardiotoxicity: A Review.
Syahputra RA; Harahap U; Dalimunthe A; Nasution MP; Satria D
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209107
[TBL] [Abstract][Full Text] [Related]
20. The Protective Role of Phenolic Compounds Against Doxorubicin-induced Cardiotoxicity: A Comprehensive Review.
Razavi-Azarkhiavi K; Iranshahy M; Sahebkar A; Shirani K; Karimi G
Nutr Cancer; 2016; 68(6):892-917. PubMed ID: 27341037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
